Sangamo Therapeutics (SGMOQ) Enterprise Value (2010 - 2025)

Sangamo Therapeutics has reported Enterprise Value for 16 years, with the latest figure at $96.7 million in Q4 2025.

• On a quarterly basis, Enterprise Value fell 44.78% year-over-year to $96.7 million in Q4 2025; TTM through Dec 2025 was $96.7 million, a 44.78% decrease from a year earlier, with the FY2025 full-year figure at $96.7 million, down 44.78% from the prior year.
• Enterprise Value was $96.7 million for Q4 2025 at Sangamo Therapeutics, down from $194.9 million in the prior quarter.
• The five-year high for Enterprise Value was $1.2 billion in Q1 2021, with the low at -$25.7 million in Q3 2023.
• Average Enterprise Value over 5 years is $357.1 million, with a median of $185.0 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value slumped 105.25% in 2023, then surged 653.72% in 2024.
• Over 5 years, Enterprise Value stood at $717.9 million in 2021, then slumped by 41.04% to $423.3 million in 2022, then plunged by 87.95% to $51.0 million in 2023, then soared by 243.56% to $175.2 million in 2024, then slumped by 44.78% to $96.7 million in 2025.
• The last three Enterprise Value figures came in at $96.7 million (Q4 2025), $194.9 million (Q3 2025), and $124.6 million (Q2 2025), per Business Quant data.